In conclusion, evaluation of the BET inhibitor ODM-207 in this first-in-human study demonstrated dose proportional exposure with reversible thrombocytopaenia and in higher dose levels, fatigue and nausea, consistent with other studies of BET inhibitors. Here, DNER is linked to Thrombocytopenia.